Literature DB >> 24964760

Ultrasound of primary thyroid non-Hodgkin's lymphoma.

Buyun Ma1, Yiping Jia2, Qian Wang3, Xinxiao Li4.   

Abstract

OBJECTIVE: The aim of this study was to review the high-frequency ultrasonography findings of primary thyroid non-Hodgkin's lymphoma (PT-NHL).
METHODS: Data of 39 patients treated for PT-NHL and 48 patients as controls were retrospectively reviewed.
RESULTS: The mean age of patients, Hashimoto's thyroiditis, marked hypoechogenicity of the lesion, asymmetrical enlargement of the thyroid, cervical lymph node enlargement, enhancement of posterior echoes, and linear echogenic septations were all more statistically significantly different in the PT-NHL group than in the control group.
CONCLUSION: Ultrasonographic characteristics predictive of PT-NHL are marked hypoechogenicity in the lesion and asymmetrical enlargement of the thyroid gland.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-frequency ultrasound; Non-Hodgkin's lymphoma; Primary; Thyroid tumor; Ultrasonography

Mesh:

Year:  2014        PMID: 24964760     DOI: 10.1016/j.clinimag.2012.04.024

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  3 in total

Review 1.  Imaging of head and neck mucosa-associated lymphoid tissue lymphoma (MALToma).

Authors:  K W S Ko; Kunwar S Bhatia; Qi Yong H Ai; Ann D King
Journal:  Cancer Imaging       Date:  2021-01-12       Impact factor: 3.909

2.  Contrast-Enhanced Ultrasound in the Differential Diagnosis of Primary Thyroid Lymphoma and Nodular Hashimoto's Thyroiditis in a Background of Heterogeneous Parenchyma.

Authors:  Lulu Yang; Haina Zhao; Yushuang He; Xianglan Zhu; Can Yue; Yan Luo; Buyun Ma
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

3.  Differential diagnosis of non-diffuse primary thyroid lymphoma and papillary thyroid carcinoma by ultrasound combined with computed tomography.

Authors:  Chanjuan Peng; Dan Yi; Ying Zhou; Jincao Yao; Bo Chen; Chen Yang; Dong Xu
Journal:  BMC Cancer       Date:  2022-08-31       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.